Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Company Overview - Kiniksa Pharmaceuticals, Ltd. (KNSA) shares increased by 5.8% to close at $21.46, supported by higher trading volume compared to normal sessions [1] - The stock has gained 3.5% over the past four weeks [1] Drug Performance - The rise in share price is linked to positive investor expectations regarding the sales growth of Kiniksa's approved drug, Arcalyst (rilonacept) [2] - Arcalyst recorded sales of $122.5 million in Q4 2024, reflecting a 72% year-over-year increase [2] - The drug was initially approved by the FDA in 2021 for recurrent pericarditis and has since expanded its label to include certain cryopyrin-associated periodic syndromes [2] - Kiniksa is also evaluating Arcalyst in a mid-stage study for treating cardiac sarcoidosis in collaboration with Mayo Clinic [2] - The company has another candidate, KPL-387, in early-stage development for recurrent pericarditis [2] Financial Expectations - Kiniksa is expected to report quarterly earnings of $0.05 per share, representing a 120% year-over-year increase [3] - Revenue expectations for the upcoming report are $127.44 million, up 59.6% from the same quarter last year [3] - The consensus EPS estimate has been revised 266.7% higher over the last 30 days, indicating a positive trend in earnings estimate revisions [4] Industry Context - Kiniksa Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry [4] - Another company in the same industry, PTC Therapeutics (PTCT), saw its stock close 4.3% lower at $52.87, with a 20.4% return over the past month [4][5] - PTC Therapeutics' consensus EPS estimate has remained unchanged at -$1.22, reflecting a year-over-year change of -1.7% [5]